1. Home
  2. FHB vs NAMS Comparison

FHB vs NAMS Comparison

Compare FHB & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FHB
  • NAMS
  • Stock Information
  • Founded
  • FHB 1858
  • NAMS 2019
  • Country
  • FHB United States
  • NAMS Netherlands
  • Employees
  • FHB N/A
  • NAMS N/A
  • Industry
  • FHB Major Banks
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • FHB Finance
  • NAMS Health Care
  • Exchange
  • FHB Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • FHB 3.0B
  • NAMS 3.1B
  • IPO Year
  • FHB 2016
  • NAMS N/A
  • Fundamental
  • Price
  • FHB $25.31
  • NAMS $40.29
  • Analyst Decision
  • FHB Sell
  • NAMS Strong Buy
  • Analyst Count
  • FHB 9
  • NAMS 10
  • Target Price
  • FHB $28.00
  • NAMS $44.80
  • AVG Volume (30 Days)
  • FHB 1.3M
  • NAMS 1.0M
  • Earning Date
  • FHB 10-24-2025
  • NAMS 11-05-2025
  • Dividend Yield
  • FHB 4.22%
  • NAMS N/A
  • EPS Growth
  • FHB 17.02
  • NAMS N/A
  • EPS
  • FHB 2.05
  • NAMS N/A
  • Revenue
  • FHB $824,314,000.00
  • NAMS $35,243,000.00
  • Revenue This Year
  • FHB $12.21
  • NAMS N/A
  • Revenue Next Year
  • FHB $2.25
  • NAMS N/A
  • P/E Ratio
  • FHB $12.04
  • NAMS N/A
  • Revenue Growth
  • FHB 1.80
  • NAMS 4.91
  • 52 Week Low
  • FHB $20.32
  • NAMS $14.06
  • 52 Week High
  • FHB $28.80
  • NAMS $41.47
  • Technical
  • Relative Strength Index (RSI)
  • FHB 60.15
  • NAMS 61.84
  • Support Level
  • FHB $23.32
  • NAMS $36.59
  • Resistance Level
  • FHB $24.90
  • NAMS $40.88
  • Average True Range (ATR)
  • FHB 0.54
  • NAMS 2.59
  • MACD
  • FHB 0.08
  • NAMS -0.09
  • Stochastic Oscillator
  • FHB 89.66
  • NAMS 90.44

About FHB First Hawaiian Inc.

First Hawaiian Inc is a bank holding company. It provides a diversified range of banking services to consumer and commercial customers, including deposit products, lending services, and wealth management and trust services. The company offers a variety of deposit products to its customers, including checking and savings accounts and other types of deposit accounts. It provides commercial and industrial lending, including auto dealer flooring, commercial real estate, and construction lending. It also offers comprehensive consumer lending services focused on residential real estate lending, indirect auto financing, and other consumer loans. The company's segments are Retail Banking, Commercial Banking, and Treasury, and others of which key revenue is derived from Retail Banking.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: